Military Medicine 2003-12-01

Military aviators, special operations forces, and causal malaria prophylaxis.

James A Chambers

Index: Mil. Med. 168(12) , 1001-6, (2003)

Full Text: HTML

Abstract

U.S. military aviators are currently restricted to the use of chloroquine or doxycycline for malaria prophylaxis. Ground forces are allowed the additional option of taking mefloquine. These medications are begun before deployment, must be taken for 4 weeks after leaving the malarious area, and primaquine must be added to the regimen the last 2 of those 4 weeks. Compliance with this regimen is often poor, especially in populations who travel abroad frequently for short periods of time. Causal malaria prophylaxis offers potential benefits of decreased length of postdeployment regimens and obviates the need for a second medication for terminal prophylaxis. Potential obstacles include adverse drug reactions, cost, and rapid development of resistance to new medications by Plasmodium species, which should be weighed against the risks to health and mission success in each deployment.


Related Compounds

Related Articles:

Uptake of the antileishmania drug tafenoquine follows a sterol-dependent diffusion process in Leishmania.

2011-11-01

[J. Antimicrob. Chemother. 66(11) , 2562-5, (2011)]

Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand.

2003-11-01

[Am. J. Trop. Med. Hyg. 69(5) , 542-7, (2003)]

A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers.

2009-08-01

[Am. J. Trop. Med. Hyg. 81(2) , 356-62, (2009)]

In-vitro interaction of tafenoquine and chloroquine in Plasmodium falciparum from northwestern Thailand.

2003-01-01

[Wien. Klin. Wochenschr. 115 Suppl 3 , 28-32, (2003)]

Risk factors for gametocyte carriage in uncomplicated falciparum malaria in children before and after artemisinin-based combination treatments.

2011-01-01

[Chemotherapy 57(6) , 497-504, (2011)]

More Articles...